Results · Apr-Jun 2026
Sandu Pharmaceuticals Q1 FY27 results
Sales fell 2% to ₹16.4 crore from ₹16.7 crore in Apr-Jun 2025.
Operating profit grew 2% to ₹0.54 crore, an operating margin of 3.3% (up 0.1 points from a year ago).
Net profit grew 2% to ₹0.23 crore from ₹0.22 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −3%, net profit +426%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 16.4 | 16.7 | −2% |
| Operating profit (EBITDA) | 0.5 | 0.5 | +2% |
| Operating margin | 3.3% | 3.1% | +0.1 pts |
| Net profit | 0.2 | 0.2 | +2% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.